Zhejiang Pharmaceutical Group to boost stake in Conba Pharmaceutical via block trade

Zhejiang Conba Pharmaceutical announced that its controlling shareholder, Zhejiang Pharmaceutical Health Industry Group Co., Ltd. (Zhejiang Pharmaceutical Group), plans to increase its stake by acquiring 50,659,020 shares (1.999% of total share capital) through a block trade. This move aims to enhance control, reflecting confidence in the company's future and long-term investment value. The transaction is scheduled between January 16, 2026, and April 15, 2026, using Zhejiang Pharmaceutical Group’s own or self-raised funds.

The shares will be transferred from Zhejiang Conba Group Co., Ltd. (Conba Group), currently the second-largest shareholder. Conba Group, along with its actual controller Mr. Hu Jiqiang, will reduce its stake by up to 50,659,020 shares (2% of total share capital) to meet its business development funding needs.

Both Zhejiang Pharmaceutical Group and Conba Group have committed to not reducing their holdings outside this block trade during the specified period. The transaction is subject to market conditions and regulatory compliance.